查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1882976

美容神经毒素市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032 年）

Aesthetic Neurotoxin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 请询问到货日

价格

美容神经毒素市场成长驱动因素

由于对微创美容手术的需求不断增长以及消费者对美容效果的接受度日益提高，全球美容神经毒素市场持续扩张。根据本报告，预计该市场在 2024 年的规模将达到 52.5 亿美元，并在 2025 年达到 56 亿美元。预计到 2032 年，该市场将进一步成长至 91.2 亿美元，预测期内复合年增长率 (CAGR) 为 7.2%。北美地区在全球市场中占领先地位，预计到 2024 年将占 51.62% 的市场占有率，这主要得益于其先进的医疗基础设施、较高的患者支出以及对美容手术的广泛接受。

美容神经毒素（通常称为肉毒桿菌注射）是一种非手术疗法，旨在实现脸部年轻化和减少皱纹。美容手术在各个年龄层的日益普及以及社会对美容手术接受度的不断提高，是推动市场成长的关键因素。此外，医疗美容旅游也显着促进了该行业的发展，例如韩国等国家国际患者就诊量激增。预计2023年将有605,768名医疗旅客到访韩国，比2022年增加144.2%。

市场动态

市场驱动因素

对微创美容疗法的需求正在蓬勃发展，尤其是在寻求早期抗衰老干预的年轻一代。根据美国美容外科学会2022年的报告，美容手术总量增加了14%，而非手术疗法则实现了显着的23%的增长。肉毒桿菌注射是最受欢迎的美容方式，预计2022年将进行887万例。已开发国家和新兴国家可支配收入的成长进一步推动了美容神经毒素的普及。

市场限制因子

儘管需求强劲，但美容神经毒素的副作用（例如肿胀、瘀伤、眼睑下垂、头痛和暂时性肌肉无力）限制了其市场发展。高昂的治疗费用也构成了一大障碍。据Direct Aesthetics PLLC称，在美国，肉毒桿菌治疗的平均费用为每次450美元，价格范围从200美元到1200美元不等。这样的价格限制了低收入患者接受治疗，并增加了假冒产品的风险。

市场机会

对更安全、更持久、免疫原性更低的神经毒素製剂的需求不断增长，推动了研发投入的增加。各公司正在开发新型重组肉毒桿菌毒素，旨在最大限度地减少副作用并延长美容效果。 2023年10月，艾伯维公司宣布了其用于治疗眉间纹的重组肉毒桿菌毒素E (BoNT/E) III期临床试验的积极结果，凸显了其产品线持续创新。

市场挑战

假神经毒素产品的氾滥对病人安全构成重大风险，并可能损害消费者对正品的信任。 2024年6月，美国疾病管制与预防中心 (CDC) 报告称，美国九个州的17人在接受假神经毒素注射后出现不良反应。此类事件对收入成长构成挑战，并凸显了严格监管的必要性。

市场趋势

技术进步，包括重组肉毒桿菌毒素的研发，是该产业的主要趋势。重组製剂具有免疫原性较低、疗效持续时间较长等优点，因此安全性较高。 2024年9月，明美生物技术有限公司的首个液态重组A型肉毒桿菌毒素製剂 "YY003" 获得美国FDA的IND批准，用于治疗眉间纹，这标誌着该行业正朝着下一代神经毒素的方向发展。

细分市场洞察

按应用领域

2024年，眉间纹细分市场占主导地位，这主要得益于市场需求旺盛以及强有力的临床证据支持其疗效。额头皱纹市场也占了相当大的占有率，这主要得益于美国FDA于2023年批准XEOMIN用于治疗多种上脸部皱纹。鱼尾纹市场也持续成长，因为这些细纹仍然是常见的美容问题。

依最终使用者划分

专科诊所和皮肤科诊所在2024年占了最大的收入占有率。广泛的美容服务和积极的医疗旅游是推动患者选择的主要因素。医院和诊所也保持了相当大的占有率，2023年美国24.5%的美容手术是在医院进行的。

区域洞察

北美地区继续保持其主导地位，在2024年市场规模达到27.1亿美元，这主要得益于较高的手术量和快速的监管审批。美国占了区域需求的大部分，2023年进行了440万例非手术美容疗程。

欧洲维持了较大的市场占有率，这得益于人口老化和皮肤再生疗法的广泛应用。

由于美容疗程的普及以及重要的区域合作，例如华东医学美容与ATGC株式会社的合作，亚太地区预计将以最高的复合年增长率增长。

由于可支配收入的增加以及诸如大元製药在卡达推出的 "NABOTA" （2025年上市）等产品的上市，拉丁美洲和中东/非洲的需求也在增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家美容手术量概览
  • 以美容手术类型划分的价格分析概览
  • 主要国家监理状况概览
  • 主要国家报销状况概览
  • 主要公司新产品发布
  • 主要公司在研产品线分析
  • 经厚生劳动省核准的主要美容神经毒素产品进口和销售概览福利（日本）

第五章：全球美容神经毒素市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 按应用领域划分
    • 额纹
    • 眉间纹
    • 鱼尾纹
    • 其他
  • 市场分析、洞察与预测 - 按最终用户划分
    • 专科诊所及皮肤科诊所
    • 医院和诊所
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美美容市场神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲化妆品神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 乌克兰
    • 欧洲其他地区

第八章：亚太地区化妆品神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 泰国
    • 台湾
    • 亚太其他地区

第九章：拉丁美洲化妆品神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 智利
    • 哥伦比亚
    • 拉丁美洲其他地区

第十章：中东和非洲化妆品神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 埃及
    • 伊朗
    • 土耳其
    • 黎巴嫩
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024 年）
  • 公司简介
    • 艾伯维公司（Allergen Aesthetics）
    • 益普生製药
    • 默兹製药
    • HUGEL 公司
    • Evolus 公司
    • 高德美
    • REVANCE
    • Supernus Pharmaceuticals 公司
    • Medytox
    • 上海復星医药（集团）有限公司
    • 大王製药药厂
Product Code: FBI113750

Growth Factors of aesthetic neurotoxin Market

The global aesthetic neurotoxin market continues to expand due to rising demand for minimally invasive cosmetic procedures and increasing consumer acceptance of aesthetic enhancements. According to the report, the market was valued at USD 5.25 billion in 2024, is expected to reach USD 5.60 billion in 2025, and is projected to grow significantly to USD 9.12 billion by 2032, reflecting a CAGR of 7.2% during the forecast period. North America led the global market in 2024 with a 51.62% share, driven by advanced healthcare infrastructure, high patient spending, and strong adoption of aesthetic procedures.

Aesthetic neurotoxins, widely recognized as botulinum toxin injections, offer a non-surgical alternative for facial rejuvenation and wrinkle reduction. The increasing normalization of aesthetic procedures across generations and growing social acceptance of cosmetic enhancements are major contributors to market growth. Additionally, cosmetic tourism significantly boosts the industry, with countries like South Korea witnessing sharp increases in foreign patient visits-605,768 medical tourists in 2023, representing a 144.2% rise from 2022.

Market Dynamics

Market Drivers

Demand for minimally invasive aesthetic treatments continues to surge, particularly among younger consumers seeking early anti-aging interventions. The Aesthetic Society's 2022 report documented a 14% rise in total aesthetic procedures and a remarkable 23% growth in non-surgical treatments. Botulinum toxin injections remained the most popular, accounting for 8.87 million procedures in 2022. Rising disposable incomes in both developed and emerging economies further fuel the uptake of aesthetic neurotoxins.

Market Restraints

Despite strong demand, adverse effects associated with aesthetic neurotoxins-such as swelling, bruising, droopy eyelids, headaches, and temporary muscle weakness-pose restraints. High treatment costs also reduce accessibility. According to Direct Aesthetics PLLC, Botox treatments in the U.S. cost an average of USD 450, ranging from USD 200 to USD 1,200 per session. Such pricing limits access for lower-income patients and increases the risk of counterfeit product use.

Market Opportunities

R&D initiatives are expanding due to rising demand for safer, long-lasting, and less immunogenic neurotoxin formulations. Companies are developing new recombinant botulinum toxins designed to minimize adverse effects and extend cosmetic benefits. In October 2023, AbbVie announced positive Phase 3 results for trenibotulinumtoxinE (BoNT/E) for glabellar lines, highlighting ongoing innovation in product pipelines.

Market Challenges

The proliferation of counterfeit neurotoxin products poses a major risk to patient safety and diminishes trust in legitimate brands. The CDC reported in June 2024 that 17 individuals across nine U.S. states experienced harmful reactions after receiving counterfeit neurotoxin injections. Such incidents challenge revenue growth and reinforce the need for strict regulatory oversight.

Market Trends

Technological advancements-including the development of recombinant botulinum toxin-represent a major industry trend. Recombinant formulations are less immunogenic and offer safer alternatives with improved duration of effect. In September 2024, MingMed Biotechnology secured U.S. FDA IND approval for YY003, the first liquid recombinant BoNT/A for glabellar lines, demonstrating industry momentum toward next-generation neurotoxins.

Segmentation Insights

By Application

The glabellar lines segment dominated the market in 2024 due to high demand and robust clinical evidence supporting treatment effectiveness. Forehead wrinkles also recorded significant share, driven by the 2023 U.S. FDA approval of XEOMIN for multiple upper facial lines. The crow's feet segment continues to expand as these fine lines remain a common aesthetic concern.

By End-User

Specialty & dermatology clinics accounted for the largest revenue share in 2024. Their wide range of cosmetic services and strong participation in medical tourism drive patient preference. Hospitals & clinics also maintained a considerable share, with 24.5% of U.S. cosmetic procedures in 2023 performed in hospital settings.

Regional Insights

North America generated USD 2.71 billion in 2024, maintaining dominance due to high procedure volume and rapid regulatory approvals. The U.S. accounted for the majority of regional demand, with 4.4 million non-surgical aesthetic procedures in 2023.

Europe held substantial share fueled by aging demographics and strong adoption of skin rejuvenation treatments.

Asia Pacific is projected to grow at the fastest CAGR, supported by normalization of cosmetic procedures and major regional collaborations-such as the partnership between Huadong Medicine Aesthetics and ATGC Co. Ltd.

Latin America and Middle East & Africa show rising demand due to growing disposable income and product launches like Daewoong's NABOTA in Qatar (2025).

Conclusion

With market revenue rising from USD 5.25 billion in 2024 to USD 9.12 billion by 2032, the aesthetic neurotoxin industry is poised for strong growth. Increased acceptance of cosmetic enhancements, technological advancements, expanding medical tourism, and strategic industry partnerships will continue to shape the global landscape.

Segmentation By Application

  • Forehead Wrinkles
  • Glabellar Lines
  • Crow's Feet
  • Others

By End-User

  • Specialty & Dermatology Clinics
  • Hospitals & Clinics
  • Others

By Region

  • North America (By Application, End-User, and Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Application, End-User, and Country)
    • Germany (By Application)
    • U.K. (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Ukraine (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Application, End-User, and Country /sub-region)
    • China (By Application)
    • India (By Application)
    • Japan (By Application)
    • Australia (By Application)
    • South Korea (By Application)
    • Thailand (By Application)
    • Taiwan (By Application)
    • Rest of the Asia Pacific (By Application)
  • Latin America (By Application, End-User, and Country /sub-region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Colombia (By Application)
    • Argentina (By Application)
    • Venezuela (By Application)
    • Chile (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Application, End-User, and Country /sub-region)
    • UAE (By Application)
    • Saudi Arabia (By Application)
    • Rest of GCC (By Application)
    • South Africa (By Application)
    • Turkey (By Application)
    • Egypt (By Application)
    • Lebanon (By Application)
    • Iran (By Application)
    • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of the Number of Aesthetic Procedures, By Key Countries
  • 4.2. Overview of Price Analysis of Types of Aesthetic Procedures
  • 4.3. Overview of Regulatory Scenario, By Key Countries
  • 4.4. Overview of Reimbursement Scenario, By Key Countries
  • 4.5. New Product Launches, By Key Players
  • 4.6. Pipeline Analysis, By Key Players
  • 4.7. Imports/Sales Overview of Key Aesthetic Neurotoxin Products Approved by MHLW (Japan)

5. Global Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Forehead Wrinkles
    • 5.1.2. Glabellar Lines
    • 5.1.3. Crow's Feet
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By End-User
    • 5.2.1. Specialty & Dermatology Clinics
    • 5.2.2. Hospitals & Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Forehead Wrinkles
    • 6.1.2. Glabellar Lines
    • 6.1.3. Crow's Feet
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By End-User
    • 6.2.1. Specialty & Dermatology Clinics
    • 6.2.2. Hospitals & Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Forehead Wrinkles
    • 7.1.2. Glabellar Lines
    • 7.1.3. Crow's Feet
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By End-User
    • 7.2.1. Specialty & Dermatology Clinics
    • 7.2.2. Hospitals & Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Scandinavia
    • 7.3.7. Ukraine
    • 7.3.8. Rest of Europe

8. Asia Pacific Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Forehead Wrinkles
    • 8.1.2. Glabellar Lines
    • 8.1.3. Crow's Feet
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By End-User
    • 8.2.1. Specialty & Dermatology Clinics
    • 8.2.2. Hospitals & Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. South Korea
    • 8.3.6. Thailand
    • 8.3.7. Taiwan
    • 8.3.8. Rest of Asia Pacific

9. Latin America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Forehead Wrinkles
    • 9.1.2. Glabellar Lines
    • 9.1.3. Crow's Feet
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By End-User
    • 9.2.1. Specialty & Dermatology Clinics
    • 9.2.2. Hospitals & Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Chile
    • 9.3.4. Colombia
    • 9.3.5. Rest of Latin America

10. Middle East & Africa Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Application
    • 10.1.1. Forehead Wrinkles
    • 10.1.2. Glabellar Lines
    • 10.1.3. Crow's Feet
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By End-User
    • 10.2.1. Specialty & Dermatology Clinics
    • 10.2.2. Hospitals & Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. Egypt
    • 10.3.2. Iran
    • 10.3.3. Turkey
    • 10.3.4. Lebanon
    • 10.3.5. UAE
    • 10.3.6. Saudi Arabia
    • 10.3.7. South Africa
    • 10.3.8. Rest of Middle East and Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc. (Allergen Aesthetics)
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Ipsen Pharma
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merz Pharma
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. HUGEL, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Evolus, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. GALDERMA
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. REVANCE
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Supernus Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Medytox
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. DAEWOONG PHARMACEUTICAL CO., LTD
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 2: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 3: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 4: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 5: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 6: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country, 2019-2032
  • Table 7: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 8: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 9: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 11: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 12: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 13: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 14: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 15: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 17: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 18: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032

List of Figures

  • Table 1: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 2: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 3: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 4: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 5: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 6: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country, 2019-2032
  • Table 7: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 8: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 9: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 11: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 12: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 13: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 14: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 15: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 17: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 18: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032